PrimeCell Therapeutics is Biotechnology in Czech Republic that focus on medicinal technologies business. Founded in 2006. They cover business area such as operator, discover and clinical testing, biological drug, medicinal technology, stem cell treatment, somatic cell therapy, tissue engineering, gene therapy, cell testing, diagnostic service, regenerative medicine, cell carrier, nano-material, human tissue, organ.
2006
( 18 years old in 2024 )
Medicinal Technologies
-
Jáchymova 26/2
Prague, 110 00
Czech Republic
Private
operatordiscover and clinical testingbiological drugmedicinal technologystem cell treatmentsomatic cell therapytissue engineeringgene therapycell testingdiagnostic serviceregenerative medicinecell carriernano-materialhuman tissueorgan
* We use standard office opening hours in near PrimeCell Therapeutics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
PrimeCell Therapeutics is Biotechnology business from Czech Republic that founded in 2006 (18 years old in 2024), PrimeCell Therapeutics business is focusing on Medicinal Technologies.
PrimeCell Therapeutics headquarter office and corporate office address is located in Jáchymova 26/2 Prague, 110 00 Czech Republic.
PrimeCell Therapeutics was founded in Czech Republic.
In 2024, PrimeCell Therapeutics is currently focus on medicinal technologies sector.
Above is snippet of Google Trends for "medicinal technologies" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with PrimeCell Therapeutics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
